WATERTOWN, Mass. — Lyndra Therapeutics®, a clinical-stage biopharmaceutical company, today announced positive data from the STARLYNG-1 (LYN-005-C-301) study, comparing the pharmacokinetic (PK) profile of oral weekly risperidone (LYN-005) with immediate-release Risperdal administered daily to adults living with schizophrenia and schizoaffective disorder. The STARLYNG-1 study is designed to bridge to the...
Latest News
Lysogene (Paris:LYS) (FR0013233475 – LYS), a gene therapy platform Company targeting central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its LYS-GM101 program, which is being studied in the recently initiated global adaptative-design clinical trial for the treatment...
Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced dosing of the first patient, at Royal Manchester Children’s Hospital, part of Manchester University NHS Foundation Trust, in the global adaptative-design clinical trial with LYS-GM101 (NCT04273269), a gene therapy for...
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced dosing of the first patient in the United States (second patient in the global adaptative-design clinical trial) with LYS-GM101 investigational gene therapy at CHOC Hospital (CHOC) in a global adaptative-design...
PARIS – Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announces that it has entered into an exclusive, worldwide license agreement with SATT Conectus for the development and commercialization of a gene therapy candidate for the treatment of Fragile X...
HOUSTON – Novel chemotherapy and biological agents for metastatic colorectal cancer, combined with surgical advances in liver resection, have resulted in a dramatic increase in survival for patients with advanced disease, according to researchers at The University of Texas M. D. Anderson Cancer Center. Published in the Journal of Clinical...
LYON, France – MaaT Pharma announced today that final results from its Phase 1/2 ODYSSEE clinical trial have been published in the journal, Nature Communications. The data demonstrated that the company’s initial product candidate, MaaT011, an autologous fecal microbiota transfer treatment, was safe and effective in fully restoring the gut microbiota in the...
LYON, France — MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, informs today on the completion of patient recruitment for the Phase 2a clinical trial sponsored by AP-HP and in collaboration...
Cambridge, Mass. – Gene therapy could potentially cure genetic diseases but it remains a challenge to package and deliver new genes to specific cells safely and effectively. Existing methods of engineering one of the most commonly used gene-delivery vehicles, adeno-associated viruses (AAV), are often slow and inefficient. Now, researchers at...
CONSHOHOCKEN, Pa. — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the Company’s Marketing Authorization Application (MAA) for resmetirom for the treatment of NASH/metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis has been validated and is now under evaluation with the...